Related Experiment Video
Updated: Jan 11, 2026

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
Published on: April 22, 2022
(Poly)phenol metabotypes and cardiometabolic health: a systematic review
Wafa Alotaibi1,2, Daniel Perrone1,3, Xiaohe Liu1
1Department of Nutritional Sciences, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, UK.
Background:
Inter-individual differences in gut microbial metabolism of dietary (poly)phenols may influence cardiometabolic outcomes, though their clinical relevance remains unclear.
Objective:
This systematic review examined associations between (poly)phenol metabotypes and cardiometabolic health.
Methods:
A comprehensive search of seven databases up to March 2025 included randomized controlled trials (RCTs) and observational studies investigating equol, O-desmethylangolensin (ODMA), and urolithin metabotypes (PROSPERO: CRD42020196149).
Results:
Thirty-three RCTs and 12 observational studies were included. Equol producers (EPs) showed lipid-lowering effects in 9 RCTs and favorable lipid profiles in 3 observational studies, while 11 RCTs and 3 studies found no differences. One RCT and 2 observational studies on ODMA producers reported inconsistent lipid outcomes. One RCT showed lipid-lowering effects for urolithin metabotype B (UM-B), while 2 observational studies linked UM-B to higher lipids vs UM-A. For blood pressure (BP), 2 RCTs and 1 study reported reductions in EPs, while 7 RCTs and 2 studies found no effects. EPs improved endothelial function in 4 RCTs, but not in 6, while no differences between metabotypes were observed in 2 studies.
Conclusion:
Evidence for the role of (poly)phenol metabotypes in cardiometabolic health is inconclusive. Further clinical studies with standardized metabotype classification and outcome measures are needed.
More Related Videos
08:21Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Related Concept Videos
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Regulation of Metabolism
Obesity
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism